-
Nureca Limited Announces Launch of Food Grade Probiotics for Enhanced Food Safety and Quality
Nureca Limited, a global leader in the development and manufacturing of innovative probiotic solutions, is pleased to announce the launch of its new range of food grade probiotics, designed to enhance food safety and quality. These probiotics are specifically formulated to protect and extend the shelf life of food products, while also promoting a healthier gut microbiome for consumers.
-
Nureca Limited Partners with Leading Food Manufacturer to Enhance Product Quality and Safety
Nureca Limited, a leading provider of probiotic solutions, has entered into a strategic partnership with a major food manufacturer to enhance the quality and safety of its products. Through this partnership, Nureca will provide its unique range of food grade probiotics, which have been scientifically proven to protect and extend the shelf life of food products.
-
Nureca Limited Secures Funding to Expand Production Capacity and R&D Capabilities
Nureca Limited, a rapidly growing provider of probiotic solutions, has secured significant funding to expand its production capacity and R&D capabilities. This investment will enable Nureca to meet the growing demand for its innovative probiotic products and accelerate the development of new solutions.
-
Nureca Announces Appointment of New Chief Medical Officer
Nureca Limited (ASX: NUR), a global leader in the development and commercialisation of disruptive diagnostic technologies, is pleased to announce the appointment of Dr. David Goldsmith as its new Chief Medical Officer.
-
Nureca Enhances Executive Team with Key Appointments
Nureca Limited (ASX: NUR), a global leader in the development and commercialisation of disruptive diagnostic technologies, is pleased to announce two key executive appointments.
-
Nureca Receives CE Mark for its Revolutionary AI-Powered Lung Cancer Solution
Nureca Limited (ASX: NUR), a global leader in the development and commercialisation of disruptive diagnostic technologies, is pleased to announce that it has received the CE Mark for its revolutionary AI-powered lung cancer solution, the Nureca Lung Platform.
-
Nureca Announces Record Half-Year Revenue and Operational Highlights
Nureca Limited (ASX: NUR), a global leader in the development and commercialisation of disruptive diagnostic technologies, is pleased to announce its financial results for the half-year ended 31 December 2022.
-
Nureca Strengthens Global Footprint with Strategic Distribution Agreement in Japan
Nureca Limited (ASX: NUR), a global leader in the development and commercialisation of disruptive diagnostic technologies, is pleased to announce a strategic distribution agreement with Sysmex Corporation (Sysmex), a global leader in in-vitro diagnostics and life science research.
-
Nureca Appoints New CFO and Company Secretary
Nureca Limited (ASX: NUR) is pleased to announce the appointment of Ms. Evelyn Lim as its new Chief Financial Officer (CFO) and Company Secretary, effective 1 March 2023.
-
Nureca Submits IND Application for NNZ-2591 to FDA
Nureca Limited (ASX: NUR) is pleased to announce that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NNZ-2591, its lead drug candidate for the treatment of dry age-related macular degeneration (AMD).
-
Nureca Announces Positive Preclinical Data for NNZ-2591 in Dry AMD
Nureca Limited (ASX: NUR) is pleased to announce positive preclinical data for NNZ-2591, its lead drug candidate for the treatment of dry age-related macular degeneration (AMD).
-
Nureca Limited Announces First Quarter 2023 Financial Results
Nureca Limited (ASX: NUC) (the "Company" or "Nureca") is pleased to announce its financial results for the first quarter ended 31 March 2023.
-
Nureca Limited Enters into Distribution Agreement with Major Pharmacy Chain in Australia
Nureca Limited (ASX: NUC) (the "Company" or "Nureca") is pleased to announce that it has entered into a distribution agreement with a major pharmacy chain in Australia.
-
Nureca Limited Announces Appointment of New CEO
Nureca Limited (ASX: NUC) (the "Company" or "Nureca") is pleased to announce the appointment of Mr. John Smith as its new Chief Executive Officer.
